Indications for urokinase
This product is mainly used for thrombolytic treatment of thromboembolic
diseases. These included acute generalized pulmonary embolism, coronary artery
embolization and myocardial infarction within 6-12 hours of chest pain, acute
cerebrovascular embolization with symptoms shorter than 3-6 hours, retinal
artery embolization, and other severe ilio-femoral vein thrombosis with
peripheral artery embolization symptoms. It is also used to prevent thrombosis
after artificial heart flap operation and to maintain the patency of vascular
intubation, thoracic cavity and pericardial cavity drainage tube. The efficacy
of thrombolytic therapy should be maintained by subsequent heparin
anticoagulation.
This product is an enzymatic thrombolytic agent, which can activate in vivo
plasminogen into plasminogen, thereby hydrolyzing fibrin to dissolve freshly
formed thrombi. For acute myocardial infarction, acute cerebral thrombosis and
cerebral vascular embolism, peripheral arteriovenous thrombosis, central retinal
arteriovenous thrombosis and other fresh thromboocclusive diseases. This product
has no obvious effect on old thrombosis. It is also applicable to the treatment
of cerebral thrombosis, peripheral vascular embolization, central retinal
vascular embolization, acute myocardial infarction and other new thromboembolic
diseases, as well as renal transplantation, orthopedic surgery and other
thrombosis, with good efficacy.